What's happening in the peptide world.
FDA actions, clinical updates, regulatory changes, and what they actually mean for researchers and the broader peptide community. Our own weekly take lives in the Dispatch; this is everyone else's headlines, annotated.
A New Review Maps the Peptides Studied for Healthy Aging
A 2026 Frontiers in Aging review maps nine peptides studied for healthy aging, from FDA-approved tirzepatide to research-only compounds. What it does and doesn't show.
Read the story →What the July PCAC Meeting Means for Your Peptides
FDA's Pharmacy Compounding Advisory Committee meets July 23-24 on the compounding status of BPC-157, TB-500, and other returned peptides. What FDA's own scientists — and a conflict-of-interest question — mean for the outcome.
Read the story →People on GLP-1 Drugs Are Moving Less, New Fitbit Data Shows
New Fitbit data presented at ENDO 2026 shows daily steps and exercise minutes decline after people start a GLP-1 medication. Here's what the study found — and why body composition, not just the scale, is worth tracking.
Read the story →Retatrutide's Phase 3 Data Just Set a New Bar — And CagriSema Isn't Far Behind
Retatrutide hit 28.3% weight loss at 80 weeks in TRIUMPH-1; CagriSema hit 22.7% in REDEFINE 1 and is under FDA review. A look at the real Phase 3 numbers behind both headlines.
Read the story →New Commentary Examines BPC-157 as a Gastrointestinal Cytoprotectant
A new Inflammopharmacology commentary examines BPC-157's GI cytoprotective properties from outside the Croatian group behind most BPC-157 research. Here's what it says and what it can't.
Read the story →GLP-1s Linked to Lower Risk Across Six of Seven Cancers
An ASCO 2026 study of 10,000+ patients found GLP-1s linked to lower risk in 6 of 7 cancers. Breast, liver, colorectal, lung significant. Observational only.
Read the story →GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in Study of 110,000 Women
Penn Medicine's study of 111,646 women found GLP-1 users had 30%–35% lower breast cancer odds. Presented at ASCO 2026. Observational — not yet causal evidence.
Read the story →Most People Who Stop GLP-1 Drugs End Up Back On Them, Conference Study Finds
Research presented at the Endocrine Society's ENDO 2026 meeting finds that stopping and restarting GLP-1 medications is more common than assumed. Here's what the data shows — and what it doesn't.
Read the story →Systematic Review Finds RCT Evidence for Peptides in Skin Aging
A 2026 peer-reviewed meta-analysis of RCTs finds measurable skin benefits from oral and topical peptides including collagen peptides and matrixyl. What the data shows.
Read the story →FDA Sends 25 Warning Letters to Telehealth Companies Over Compounded GLP-1 Claims
FDA issued 25 warning letters to telehealth firms over compounded GLP-1 marketing claims in June 2026. What the letters target and how to read the claims.
Read the story →The Largest Study Yet Found GLP-1 Users Had a Lower Risk of Obesity-Related Cancers, With a Bigger Effect in Women
A target-trial emulation presented at ASCO 2025 followed adults with diabetes and obesity and found GLP-1 users had a 7% lower risk of obesity-related cancer and an 8% lower risk of death than users of an older diabetes drug. The reductions were largest for colon and rectal cancer, and the benefit was clearer in women than men.
Read the story →An Oral GLP-1 Pill Heads to Phase III: What the Elecoglipron Data Actually Show
AstraZeneca's oral GLP-1 elecoglipron showed 10.5% weight loss in Phase 2b and is advancing to Phase III. What the VISTA and SOLSTICE data show — and their limits.
Read the story →Postmenopausal Women Lost 35% More Weight on Tirzepatide When They Were Also on Hormone Therapy
A Mayo Clinic retrospective study published in The Lancet found postmenopausal women using tirzepatide plus hormone therapy lost significantly more weight than those on tirzepatide alone: 17% vs 14% body weight reduction, with nearly triple the rate of major weight loss.
Read the story →Medicare Will Cover GLP-1s for Weight Loss at $50 a Month Starting July 1
CMS confirmed the Medicare GLP-1 Bridge: eligible Part D beneficiaries get Wegovy, Zepbound, or Foundayo for a $50 monthly copay from July 2026 through 2027. Here's who qualifies and how it compares to cash prices.
Read the story →GLP-1 Drugs Linked to Significantly Lower Risk of Knee Replacement Surgery
A large peer-reviewed study published June 2026 found semaglutide and tirzepatide may reduce knee replacement risk by nearly 5 percentage points over 8 years.
Read the story →FDA Moves to End Large-Scale Compounding of Semaglutide and Tirzepatide — Comment Period Closes June 29
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment window closes June 29, 2026. Here's what it means.
Read the story →Amazon Removed Bacteriostatic Water from Its Marketplace. Here's the Data Behind Why.
In March 2026, third-party testing found 9 of 11 bacteriostatic water products on Amazon failed basic quality standards. Amazon removed the category shortly after. Here's what the data actually showed.
Read the story →Which Peptides Could Get FDA Compounding Approval This Summer - and What That Actually Means
The FDA removed 12 peptides from its restricted list in April 2026, and a July advisory committee meeting could clear 7 more for legal compounding. Here's what's actually happening and what it means.
Read the story →